Skip to Content

Lamictal XR Approval History

  • FDA approved: Yes (First approved May 29th, 2009)
  • Brand name: Lamictal XR
  • Generic name: lamotrigine
  • Dosage form: Extended Release Tablets
  • Company: GlaxoSmithKline
  • Treatment for: Seizures

Lamictal XR (lamotrigine) is a once-daily antiepileptic drug indicated as adjunctive therapy for partial onset seizures with or without secondary generalization and primary generalized tonic-clonic seizures in patients 13 years of age or older. Lamictal XR is also indicated for conversion to monotherapy for the treatment of partial onset seizures.

Development History and FDA Approval Process for Lamictal XR

Apr 26, 2011Approval FDA Approves Lamictal XR (Lamotrigine) for Conversion to Monotherapy for Treatment of Partial Seizures in Appropriate Patients
Feb  5, 2010Approval FDA Approves Once-A-Day Lamictal XR as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.